PCSA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 115070 min ago

@ $2.43

Išleistas: 12 vas. 2024 @ 22:26

Grąža: -7.41%

Ankstesnis signalas: vas. 6 - 21:26

Ankstesnis signalas: Pardavimas

Grąža: 0.00 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 21:07):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Šios dienos apimtis	66 001.00
Vidutinė apimtis	1.52M
Rinkos kapitalizacija	6.43M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.270
ATR14	$0.0100 (0.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.32
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Tūris Koreliacija

Ilgas: 0.38 (neutral)

Trumpas: -0.58 (weak negative)

Signal:(43.886) Neutral

Processa Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Processa Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.39
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.20
( neutral )

0.61
( weak )

0.32
( neutral )

Processa Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2023
Pajamos:	$0
Bruto pelnas:	$-222.00 (0.00 %)
EPS:	$-8.48

FY	2022
Pajamos:	$0
Bruto pelnas:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.